Literature DB >> 33834259

SUMOylation modulates the stability and function of PI3K-p110β.

Ahmed El Motiam1, Carlos F de la Cruz-Herrera2, Santiago Vidal1, Rocío Seoane1, Maite Baz-Martínez1, Yanis H Bouzaher1, Emilio Lecona3, Mariano Esteban4, Manuel S Rodríguez5,6, Anxo Vidal1, Manuel Collado7, Carmen Rivas8,9.   

Abstract

Class I PI3K are heterodimers composed of a p85 regulatory subunit and a p110 catalytic subunit involved in multiple cellular functions. Recently, the catalytic subunit p110β has emerged as a class I PI3K isoform playing a major role in tumorigenesis. Understanding its regulation is crucial for the control of the PI3K pathway in p110β-driven cancers. Here we sought to evaluate the putative regulation of p110β by SUMO. Our data show that p110β can be modified by SUMO1 and SUMO2 in vitro, in transfected cells and under completely endogenous conditions, supporting the physiological relevance of p110β SUMOylation. We identify lysine residue 952, located at the activation loop of p110β, as essential for SUMOylation. SUMOylation of p110β stabilizes the protein increasing its activation of AKT which promotes cell growth and oncogenic transformation. Finally, we show that the regulatory subunit p85β counteracts the conjugation of SUMO to p110β. In summary, our data reveal that SUMO is a novel p110β interacting partner with a positive effect on the activation of the PI3K pathway.

Entities:  

Keywords:  SUMO; Stability; Transformation; p110β; p85β

Mesh:

Substances:

Year:  2021        PMID: 33834259     DOI: 10.1007/s00018-021-03826-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  36 in total

1.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.

Authors:  Sohye Kang; Adam Denley; Bart Vanhaesebroeck; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 2.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

3.  SH2 domains recognize specific phosphopeptide sequences.

Authors:  Z Songyang; S E Shoelson; M Chaudhuri; G Gish; T Pawson; W G Haser; F King; T Roberts; S Ratnofsky; R J Lechleider
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

4.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

5.  Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.

Authors:  J Yu; Y Zhang; J McIlroy; T Rordorf-Nikolic; G A Orr; J M Backer
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

6.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

Authors:  Jean J Zhao; Zhenning Liu; Li Wang; Eyoung Shin; Massimo F Loda; Thomas M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

7.  Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

Authors:  Kohjiro Ueki; David A Fruman; Saskia M Brachmann; Yu-Hua Tseng; Lewis C Cantley; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 8.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

9.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 10.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

View more
  4 in total

1.  SENP1 regulates the transformation of lung resident mesenchymal stem cells and is associated with idiopathic pulmonary fibrosis progression.

Authors:  Wei Sun; Xiaoshu Liu; Xiaoyu Yang; Xiaoyan Jing; Chunyan Duan; Ganghao Yang; Chi Wu; Hui Huang; Qun Luo; Shu Xia; Qian Zhang; Yang Yang; Zuojun Xu
Journal:  Cell Commun Signal       Date:  2022-07-14       Impact factor: 7.525

2.  SUMOylation of Nuclear γ-Actin by SUMO2 supports DNA Damage Repair against Myocardial Ischemia-Reperfusion Injury.

Authors:  Wei Zhao; Xiuying Zhang; Jia Zhao; Ni Fan; Jianhui Rong
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

3.  Regulation of transforming growth factor-β signalling by SUMOylation and its role in fibrosis.

Authors:  Xinyi Wang; Ting Liu; Yifei Huang; Yifeng Dai; Hui Lin
Journal:  Open Biol       Date:  2021-11-10       Impact factor: 6.411

Review 4.  Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression.

Authors:  Chen Xue; Ganglei Li; Juan Lu; Lanjuan Li
Journal:  Signal Transduct Target Ther       Date:  2021-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.